Source link : https://www.newshealth.biz/health-news/novel-jak1-inhibitor-hits-the-mark-in-arthritis-trial/
TOPLINE: Ivarmacitinib, a novel Janus kinase 1 inhibitor, alleviates symptoms, reduces disease activity, and improves physical function and quality of life in patients with moderate to severe rheumatoid arthritis (RA) who have an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). METHODOLOGY: This phase 3 trial, conducted across 59 sites in China, evaluated the […]
Author : News Health
Publish date : 2024-12-23 06:17:26
Copyright for syndicated content belongs to the linked Source.